Recent Updates
Recently added Catalysts

Adjuvanted pandemic influenza candidate vaccine

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jul 23, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment5,075
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00319098Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and AbovePHASE3 COMPLETED 5,075May 1, 2006Jul 31, 2007Jul 23, 201840 Estonia, France +5
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects With Solicited Local Symptoms
During a 7 day follow-up period after each dose of vaccine and overall.

Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of symptom regardless of intensity grade. Grade 3 Pain = pain that prevented normal everyday activities Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond (\>) 50 millimeters (mm) in diameter

Number of Subjects With Solicited General Symptoms (Dose 1)
During the 7-day (Days 0-6) after Dose 1

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (\>) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.

Number of Subjects With Solicited General Symptoms (Dose 2)
During the 7-day (Days 0-6) after Dose 2

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (\>) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.

Number of Subjects With Solicited General Symptoms (Across Doses)
During the 7-day (Days 0-6) post vaccination across dosses

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (\>) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.

Number of Subjects With Unsolicited Adverse Events (AEs)
During the 21st Day (Days 0-20) post Dose 1

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.

Number of Subjects With AEs
During the 30 Day (Days 0-29) post Dose 2

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.

Number of Subjects With Serious Adverse Events (SAEs)
From Day 0 to Day 180

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Number of Subjects With New Onset Chronic Diseases (NOCDs)
From Day 0 to Day 180

NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.

Number of Subjects With Medically Significant Conditions (MSCs)
From Day 0 to Day 51

MSCs prompting emergency room or physician visits that were not related to common diseases or routine visits. Common diseases included upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.

Secondary Endpoints
Anti- Haemagglutinin Antibody (Anti-HA) Titers Against Avian Influenza A Subtype H5N1
At Day 0 (PRE), 21 and 42
Number of Seroconverted Subjects Against H5N1
At Day 21 and Day 42
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam Influenza Strain
At Day 21 and Day 42
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GSK1562902A GroupEXPERIMENTALMale and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
Fluarix+Placebo GroupACTIVE_COMPARATORMale and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
Interventions
NameTypeDescription
Adjuvanted pandemic influenza candidate vaccineBIOLOGICAL2 doses, intramuscular injection
FluarixBIOLOGICALOne intramuscular injection
PlaceboBIOLOGICALOne intramuscular injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites40

Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol. * A male or female aged 18 years or above at the time of the first vaccination. * Written informed consent obtained from the subject. * Healthy subjects as established b...

Countries:EstoniaFranceGermanyNetherlandsRussiaSpainSweden
Unlock Eligibility Criteria